Back to discover
Disease

Lipid Metabolism Disorders

Late-stage therapeutic developmentEmerging research
MeSHLipid Metabolism Disorders
2
Publications
12
Clinical trials
2024
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 clinical trial expected to report results, the earliest in Q3 2027.
Upcoming Milestones
Clinical Milestones2View
Results expected 1
Recently completed 1
Activity timeline2

Clinical trials

8 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
12
All trials
2
Active
4
Late-stage
6
Completed
Late-stage studies

A 12-week, Multicenter, Double-blind, Double-dummy, Randomized, Active-controlled, Parallel-group Study to Assess the Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily Compared to Fluvastatin Sodium Immediate Release Capsules 40 mg Twice Daily (BID) in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia at Moderate or High Cardiovascular Risk Who Did Not Achieve Their Lipid Goals When Treated With Fluvastatin Sodium Immediate Release Capsules 40 mg QD

Phase 4 · Completed · Novartis Pharmaceuticals

An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia

Phase 3 · Completed · Kastle Therapeutics, LLC

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Mipomersen as Add-on Therapy in Homozygous Familial Hypercholesterolemia Subjects

Phase 3 · Completed · Kastle Therapeutics, LLC

Fixed Combination for Lipid and Blood Pressure Control. Randomized Cross-over Study

Phase 4 · Withdrawn · Charles University, Czech Republic
Recently completed

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3561774 in Adults With Mixed Dyslipidemia

Phase 2 · Completed · Eli Lilly and Company

Vitamin D Supplementation on Metabolic Syndrome Indicators Among Food Insecure, Vitamin D Deficient Older Adults in Karaj City, Alborz Province, Iran;

Phase 2 · Completed · Alborz Medical University

An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia

Phase 3 · Completed · Kastle Therapeutics, LLC

A Phase 2 Pilot Study to Assess the Safety and Efficacy of CAT-2003 in Patients With Severe Hypertriglyceridemia

Phase 2 · Completed · Catabasis Pharmaceuticals

A 12-week, Multicenter, Double-blind, Double-dummy, Randomized, Active-controlled, Parallel-group Study to Assess the Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily Compared to Fluvastatin Sodium Immediate Release Capsules 40 mg Twice Daily (BID) in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia at Moderate or High Cardiovascular Risk Who Did Not Achieve Their Lipid Goals When Treated With Fluvastatin Sodium Immediate Release Capsules 40 mg QD

Phase 4 · Completed · Novartis Pharmaceuticals

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Mipomersen as Add-on Therapy in Homozygous Familial Hypercholesterolemia Subjects

Phase 3 · Completed · Kastle Therapeutics, LLC

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20202024
Major themes5
  • Kidney1
  • Lipid Metabolism1
  • Lipid Metabolism Disorders1
  • Liver1
  • Metabolic Syndrome1
Leading journals2
  • International journal of biological sciences1
  • Nutrients1
Leading researchers8
  • Kim HS1
  • Ko SH1
  • Li P1
  • Peng X1
  • Rong J1
  • Zhang Z1
  • Zhao T1
  • Zhong Y1
Affiliations (unnormalised)4
  • College of Human Ecology1
  • College of Life Science and Technology1
  • Institute of Clinical Medical Sciences1
  • Longhua Hospital Shanghai University of Traditional Chinese Medicine1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Pathological conditions resulting from abnormal anabolism or catabolism of lipids in the body.

Identifiers
MeSHLipid Metabolism Disorders
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.